Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Fri, Jan 16th, 2026

Biotechnology ETFs

A list of publicly traded biotechnology and biotech-related stocks and ETFs.
Fri, Jan 16th, 2026

Biotechnology (biotech) ETFs are publicly traded companies that develop pharmaceutical drugs used in the treatment of disease. You can use Barchart's Biotech Stocks list to find investment opportunities and compare stocks involved in this hot industry.

View Profiles of these companies.

Biotechnology ETFs News

Gamble on Huge Gains with These 3 Best Biotech Stocks to Buy for 2026

Investing in these three biotech stocks can offer investors with a high-risk profile the opportunity to generate outsized gains over the next decade.

LGND : 196.08 (-0.23%)
KNSA : 37.92 (-4.15%)
ASND : 215.04 (-1.05%)
Novo Nordisk Is Getting a Major Boost from Amazon for Its New Wegovy Pill. Does That Make NVO Stock a Buy Here?

Novo Nordisk shares inch higher as the pharma giant announces an oral Wegovy partnership with Amazon Pharmacy. Here’s why NVO stock is worth owning at current levels.

NVO : 57.12 (-3.04%)
LLY : 1,032.97 (-3.76%)
The 3 Best Cannabis Stocks to Buy for 2026

These three cannabis stocks mix regulatory optionality, steady operators, and biotech risk as investors position for 2026 reform tailwinds.

CRBP : 8.17 (-1.09%)
MAPS : 0.8388 (-1.18%)
GTBIF : 8.2700 (-1.08%)
Should You Chase the Rally in Alumis Stock Today?

Alumis shares soar as the biotech firm’s envudeucitinib meets all primary and secondary endpoints in a Phase 3 trial. Here’s how you should play ALMS shares in 2026.

JNJ : 219.57 (+0.47%)
ALMS : 24.17 (-0.70%)
BMY : 56.62 (-0.70%)
The Next GEICO? Michael Burry Is Pounding the Table on This 1 Warren Buffett-Esque Stock.

The famed Big Short investor is advocating for a long position in this healthcare stock.

MOH : 193.74 (+2.57%)
Up 91% in the Past Year, Is This Biotech Stock Red Hot or a Red Flag?

Puma Biotechnology (PBYI) relies on one product. It has weak fundamentals and has struggled to grow sales. PBYI stock has surged 91% over the past year, driven by technical momentum and speculative trading...

PBYI : 6.38 (-0.62%)
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar